Targeting Relapsed Multiple Myeloma with Elranatamab: A Bispecific Antibody Approach

Elranatamab, an IgG2 bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 on T cells, is a promising therapeutic option for relapsed or refractory multiple myeloma (RRMM), a hematologic malignancy with limited therapeutic options to date. Elranatamab represents a therapeutic breakthrough in the management of patients with RRMM. Bispecific antibodies targeting cytotoxic immune effector cells (including T cells) and malignant plasma cells have demonstrated a high response rate, especially in patients with penta-refractory disease. Elranatamab activates T cells, which mount a targeted and deadly attack on myeloma cells, leading to a more targeted treatment of the disease. Clinical trials showed encouraging efficacy in heavily pretreated patients, with impressive responses and an acceptable safety profile, including manageable cytokine release syndrome (CRS) and other immune-related adverse effects. Despite these recent advances that have accelerated progress, multiple myeloma remains an incurable disease, and patients often relapse with resistance to available treatments. With the evolving treatment landscape for multiple myeloma, informed by recent clinical trial data and new combination regimens, these drugs may play a crucial role in overcoming drug resistance and improving long-term patient survival.